IDEXX Laboratories, Inc. $IDXX Stock Position Raised by Pacer Advisors Inc.

Pacer Advisors Inc. grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 193.6% in the 1st quarter, Holdings Channel reports. The institutional investor owned 41,003 shares of the company’s stock after acquiring an additional 27,038 shares during the period. Pacer Advisors Inc.’s holdings in IDEXX Laboratories were worth $23,039,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Harbour Investments Inc. increased its holdings in IDEXX Laboratories by 13.3% in the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock worth $92,000 after buying an additional 16 shares during the last quarter. Prime Capital Investment Advisors LLC lifted its stake in IDEXX Laboratories by 0.5% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 3,923 shares of the company’s stock valued at $2,654,000 after acquiring an additional 18 shares during the last quarter. Pinnacle Associates Ltd. grew its position in IDEXX Laboratories by 1.5% in the fourth quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company’s stock worth $830,000 after acquiring an additional 18 shares in the last quarter. Triad Wealth Partners LLC grew its position in IDEXX Laboratories by 3.1% in the first quarter. Triad Wealth Partners LLC now owns 600 shares of the company’s stock worth $337,000 after acquiring an additional 18 shares in the last quarter. Finally, Advisory Services Network LLC increased its stake in shares of IDEXX Laboratories by 2.5% during the 4th quarter. Advisory Services Network LLC now owns 752 shares of the company’s stock worth $509,000 after purchasing an additional 18 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $567.84 on Tuesday. IDEXX Laboratories, Inc. has a one year low of $518.55 and a one year high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The stock’s fifty day simple moving average is $557.53 and its 200 day simple moving average is $588.43. The firm has a market cap of $44.79 billion, a price-to-earnings ratio of 41.81, a P/E/G ratio of 3.06 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the company posted $2.91 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on IDXX shares. Citigroup assumed coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, July 29th. Finally, UBS Group decreased their price target on shares of IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating on the stock in a research report on Monday, July 27th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $749.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.